A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis
Phase of Trial: Phase III
Latest Information Update: 12 May 2017
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms SIERRAS
- Sponsors FibroGen
- 24 Feb 2017 Planned number of patients changed from 600 to 820.
- 24 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 24 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.